ES2269746T3 - Compuestos, que son potentes inhibidores del mecanismo de intercambio na+/ca2+ y que son utiles en el tratamiento de arritmias. - Google Patents

Compuestos, que son potentes inhibidores del mecanismo de intercambio na+/ca2+ y que son utiles en el tratamiento de arritmias. Download PDF

Info

Publication number
ES2269746T3
ES2269746T3 ES02755036T ES02755036T ES2269746T3 ES 2269746 T3 ES2269746 T3 ES 2269746T3 ES 02755036 T ES02755036 T ES 02755036T ES 02755036 T ES02755036 T ES 02755036T ES 2269746 T3 ES2269746 T3 ES 2269746T3
Authority
ES
Spain
Prior art keywords
yloxy
chroman
phenylchroman
nmr
mhz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02755036T
Other languages
English (en)
Spanish (es)
Inventor
Tuula Koskelainen
Leena Otsomaa
Arto Karjalainen
Pekka Kotovuori
Jukka Tenhunen
Sirpa Rasku
Pentti Nore
Eija Tiainen
Olli Tormakangas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Oyj filed Critical Orion Oyj
Application granted granted Critical
Publication of ES2269746T3 publication Critical patent/ES2269746T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/90—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a six-membered aromatic ring, e.g. amino-diphenylethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
ES02755036T 2001-07-10 2002-07-10 Compuestos, que son potentes inhibidores del mecanismo de intercambio na+/ca2+ y que son utiles en el tratamiento de arritmias. Expired - Lifetime ES2269746T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20011507 2001-07-10
FI20011507A FI20011507A0 (fi) 2001-07-10 2001-07-10 Uusia yhdisteitä

Publications (1)

Publication Number Publication Date
ES2269746T3 true ES2269746T3 (es) 2007-04-01

Family

ID=8561628

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02755036T Expired - Lifetime ES2269746T3 (es) 2001-07-10 2002-07-10 Compuestos, que son potentes inhibidores del mecanismo de intercambio na+/ca2+ y que son utiles en el tratamiento de arritmias.

Country Status (27)

Country Link
US (1) US7425568B2 (enExample)
EP (1) EP1412343B1 (enExample)
JP (1) JP4113839B2 (enExample)
KR (1) KR20040025697A (enExample)
CN (1) CN1281597C (enExample)
AR (1) AR036236A1 (enExample)
AT (1) ATE338038T1 (enExample)
AU (1) AU2002321339B2 (enExample)
BR (1) BR0211070A (enExample)
CA (1) CA2452918C (enExample)
DE (1) DE60214388T2 (enExample)
DK (1) DK1412343T3 (enExample)
EA (1) EA006580B1 (enExample)
ES (1) ES2269746T3 (enExample)
FI (1) FI20011507A0 (enExample)
HR (1) HRP20040133A2 (enExample)
HU (1) HUP0400391A3 (enExample)
IL (2) IL159647A0 (enExample)
MX (1) MXPA04000267A (enExample)
NO (1) NO20035821L (enExample)
NZ (1) NZ530490A (enExample)
PL (1) PL367958A1 (enExample)
PT (1) PT1412343E (enExample)
RS (1) RS50886B (enExample)
UA (1) UA76168C2 (enExample)
WO (1) WO2003006452A1 (enExample)
ZA (1) ZA200400145B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20030030A0 (fi) * 2003-01-09 2003-01-09 Orion Corp Uusia yhdisteitä
US8017649B2 (en) 2005-03-11 2011-09-13 Howard Florey Institute Of Experimental Physiology And Medicine Flavonoid compounds and uses thereof
JP5941637B2 (ja) * 2011-09-12 2016-06-29 サノフイ 置換２−（クロマン−６−イルオキシ）−チアゾール及び医薬としてのその使用
EP2567958B1 (en) 2011-09-12 2014-10-29 Sanofi Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
CA2846347C (en) * 2011-09-12 2019-05-21 Sanofi Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
US8912224B2 (en) 2011-09-12 2014-12-16 Sanofi Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
CN102993195B (zh) * 2011-09-14 2017-05-17 赛诺菲 取代的2‑(色满‑6‑基氧基)噻唑及其作为药物的用途
CN103030646B (zh) * 2011-09-29 2016-08-24 上海恒瑞医药有限公司 苯并二氧六环类衍生物、其制备方法及其在医药上的应用
TWI633095B (zh) * 2013-03-08 2018-08-21 賽諾菲公司 經取代－６－基氧基－環烷類及其作為醫藥品之用途
GB201416186D0 (en) 2014-09-12 2014-10-29 Redx Pharma Ltd Compounds
WO2019175464A1 (en) 2018-03-14 2019-09-19 Orion Corporation Compounds useful as inhibitors of sodium-calcium exchanger (ncx)
US11858930B2 (en) 2020-07-28 2024-01-02 Jazz Pharmaceuticals Ireland Limited Fused bicyclic RAF inhibitors and methods for use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2820817A (en) * 1954-02-04 1958-01-21 Mcneilab Inc Oxygenated indan compounds and method of making the same
US3862232A (en) * 1963-07-03 1975-01-21 Upjohn Co 1-(p-hydroxyphenyl)-2-phenyl-6-(2-diethylaminoethoxy)-3,4-dihydronaphthalene and the salts thereof
BE650081A (enExample) 1963-07-03
GB1154119A (en) 1968-05-20 1969-06-04 Merck Ag E 3-Alkyl-Flavanones
FR2733685B1 (fr) 1995-05-05 1997-05-30 Adir Utilisation des derives du benzopyrane pour l'obtention de compositions pharmaceutiques destinees au traitement des pathologies liees a l'echangeur c1-/hc03-, na+ independant
JPH0967336A (ja) 1995-09-04 1997-03-11 Kanebo Ltd 新規なイソチオウレア誘導体
AU726239B2 (en) 1997-03-27 2000-11-02 Taisho Pharmaceutical Co., Ltd. 2-phenoxyaniline derivatives
JPH1149752A (ja) 1997-08-05 1999-02-23 Taisho Pharmaceut Co Ltd フェノキシピリジン誘導体
DE19742508A1 (de) 1997-09-26 1999-04-01 Hoechst Marion Roussel De Gmbh Sulfonamid-substituierte Chromane, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
US6162832A (en) 1997-10-20 2000-12-19 Taisho Pharmaceutical Co., Inc. 2-Phenoxyaniline derivatives
JPH11302235A (ja) 1998-04-15 1999-11-02 Taisho Pharmaceut Co Ltd フェノキシアルキルアミン誘導体
AU4360200A (en) 1999-04-23 2000-11-10 Bristol-Myers Squibb Company Bicyclic acyl guanidine sodium/proton exchange inhibitors and method
US6589983B1 (en) 1999-09-17 2003-07-08 Nissan Chemical Industries, Ltd. Benzopyran derivative
FI20030030A0 (fi) 2003-01-09 2003-01-09 Orion Corp Uusia yhdisteitä

Also Published As

Publication number Publication date
US20040235905A1 (en) 2004-11-25
NZ530490A (en) 2005-12-23
DE60214388T2 (de) 2007-09-13
EP1412343B1 (en) 2006-08-30
DK1412343T3 (da) 2007-01-02
DE60214388D1 (de) 2006-10-12
RS604A (sr) 2006-12-15
JP4113839B2 (ja) 2008-07-09
RS50886B (sr) 2010-08-31
HUP0400391A2 (hu) 2004-12-28
AU2002321339B2 (en) 2007-06-21
CN1281597C (zh) 2006-10-25
EP1412343A1 (en) 2004-04-28
AR036236A1 (es) 2004-08-25
BR0211070A (pt) 2004-06-15
EA006580B1 (ru) 2006-02-24
MXPA04000267A (es) 2004-07-23
HUP0400391A3 (en) 2008-03-28
PT1412343E (pt) 2006-12-29
PL367958A1 (en) 2005-03-07
CA2452918A1 (en) 2003-01-23
WO2003006452A1 (en) 2003-01-23
KR20040025697A (ko) 2004-03-24
NO20035821L (no) 2004-02-24
EA200400161A1 (ru) 2004-06-24
ATE338038T1 (de) 2006-09-15
ZA200400145B (en) 2005-04-08
IL159647A0 (en) 2004-06-01
US7425568B2 (en) 2008-09-16
CA2452918C (en) 2010-02-16
UA76168C2 (en) 2006-07-17
HK1068611A1 (en) 2005-04-29
CN1525966A (zh) 2004-09-01
IL159647A (en) 2008-04-13
JP2005504738A (ja) 2005-02-17
HRP20040133A2 (en) 2004-08-31
FI20011507A0 (fi) 2001-07-10

Similar Documents

Publication Publication Date Title
ES2269746T3 (es) Compuestos, que son potentes inhibidores del mecanismo de intercambio na+/ca2+ y que son utiles en el tratamiento de arritmias.
CN100457752C (zh) 用于抑制钠/钙交换体系的吡啶衍生物
ES2294475T3 (es) Derivados de nicotinamida g-sustituidos como antagonistas de receptores de opioides.
PT699185E (pt) Derivados de guanidina inibidores da permuta na+/h+ nas celulas
AU2004232604B2 (en) CaSR antagonists
AU2002321339A1 (en) New compounds, which are potent inhibitors of NA+/CA2+ exchange mechanism and are useful in the treatment of arrhythmias
US5834471A (en) Amide derivatives as 5HT1D receptor antagonists
Patel et al. Design, synthesis and antitubercular evaluation of novel series of N-[4-(piperazin-1-yl) phenyl] cinnamamide derivatives
IE921489A1 (en) Substituted carboxylic acid derivatives
JPS5835989B2 (ja) 置換ジフエニルエ−テル類
ES2251827T3 (es) Derivado de piridina y producto farmaceutico que lo contiene.
JPWO2015030189A1 (ja) 新規芳香族化合物およびその用途
DE69406350T2 (de) Pyridinederivate, die die Kaliumkanäle öffnen
RU2644234C2 (ru) Новое производное бифенила и способ его получения
Corsano et al. Novel and highly selective postsynaptic α-adrenoreceptor antagonists: synthesis and structure-activity relationships of alkane-bridged [4-(phenoxyethyl)-1-piperazinyl]-3 (2H)-pyridazinones
Metz et al. Cloxacepride and related compounds: A new series of orally active antiallergic compounds
TW201326168A (zh) 做為trpv3調節劑的稠合嘧啶衍生物
Markaryan et al. Synthesis and antiarrhythmic properties of N-acylamino derivatives of 1, 6, 7-substituted 1, 2, 3, 4-tetrahydroisoquinoline-4-spirocyclopentanes and their analogs
JPH0569831B2 (enExample)
JPWO1999026919A1 (ja) ビフェニルアミジン誘導体